Synthego is a company that provides genetically engineered cells to scientists and researchers. The company's CEO, Paul Dabrowski, fears that in the future, only a handful of people with the ability to afford will be able to acquire genetic technology that can reshape the world.
That's why Dabrowski wants to start Synthego – democratizing ways to acquire new technologies, and providing scientists, researchers, and consumers with new ways to rewrite code that defines human survival.
“People talk about the opportunity to get a tool, but the problem is getting treatment,†Dabrowski said. "We are not talking about the foundation of humanity now, but the human foundation for the next 100 years."
Now, the company has received $110 million in cash financing from new investors at Founders Fund and former supporters of the company, 8VC and Menlo Ventures, and plans to use the funds to reduce costs.
"This new funding allows us to expand our reach at a perfect time and build our full platform capabilities," Synthego co-founder and CEO Dabrowski said in a statement. "With the upcoming therapeutic cells and gene therapy, biomedicine is at the forefront of a revolution, and we are proud to support this industry."
Although Dabrowski said the funds will be used for further research and development and to bring new services to market, in the short term, the funds will be used to expand the company's two main areas of interest. One is to create a CRISPR kit that creates different gene lines based on the requirements of researchers and scientists, and the other is to create "clinical grade" materials, which means they can be used on animal (and potential human) subjects. Clinical trials.
“Overall, the demand for these products is quite high. We need to build predictability and develop informatics models for CRISPR research.â€
Overall, the Redwood, Calif.-based company has raised $166 million in funding to develop its technology, making the development of the genetic editing tool CRISPR more economical and faster for researchers. Synthego claims that by providing researchers with one-click access to engineered cells and ensuring that they are edited in their desired goals, the company can reduce the time required to conduct experiments by a few months in cell and gene therapy research and Predictable and fast results are achieved in development.
As we have written before, Synthego introduced the first CRISPR product to the market earlier this year.
Dabrowski said that people have two basic functions to use with CRISPR. The first is to remove genes or functions, and the second is to add function to genetic material.
Both of these processes involve three (very complex) steps. First, scientists must identify the genes they want to target and then understand which of the genes they want to remove. Then, a research team will need to identify and obtain the reagents and ingredients they need to edit the gene. Finally, the team needs to figure out if the editor was successful and observe the results when the edited genetic material is nurtured.
Synthego's first product line is designed to simplify the process of identifying and designing genetic material for experimentation. The next set of tools should help scientists by providing them with the materials they want to observe or experiment with.
Dabrowski said in a statement: "Our vision is that cell and gene therapy can eventually be as popular as vaccines, so that everyone can benefit from next-generation therapies. Synthego will continue to innovate and help researchers redefine revolutionary drugs. limit."
Frozen Seafood Mix,Mixed Seafood Bags,Frozen Seafood Mix Bags,Frozen Seafood Cocktail
Zhoushan Haiwang Seafood Co., Ltd. , https://www.haiwangseafoods.com